Cordis Parries Taxus Approval Thrust With REALITY Procedure Success Data
This article was originally published in The Gray Sheet
Executive Summary
Post-market surveillance of Boston Scientific's Taxus paclitaxel-eluting stent will cover over 3,500 patients and include five-year follow-up on more than 1,500 patients treated in pre-market trials